Discover ongoing clinical trials that may further our pipeline.

Motixafortide (BL-8040)
STUDY

Investigator-initiated Phase 2 Study with combination chemotherapy (Gemcitabine and Nab-Paclitaxel), BL-8040, and Immune Checkpoint Blockade (Cemiplimab) in METastatic Treatment naïve PANCreas Adenocarcinoma

CONDITION

Metastatic pancreatic cancer

PHASE
Phase 2
STAGE
Recruiting
AGENT(S)

BL-8040 + Cemiplimab
(Libtayo) + Chemo

INFORMATION
NCT04543071
STUDY

Investigator-initiated Motixafortide and Natalizumab in Sickle Cell Disease (SCD)

CONDITION

Sickle cell disease

PHASE
Phase 1
STAGE
Recruiting
AGENT(S)
INFORMATION
NCT05618301
STUDY

Investigator-initiated Phase 1b, open-label study designed to evaluate the safety of BL-8040 (a CXCR4 antagonist) in patients with acute respiratory distress syndrome (ARDS) secondary to COVID-19 and other respiratory viral infections

CONDITION

ARDS secondary to COVID-19 and other respiratory viral infections

PHASE
Phase 1b
STAGE
Recruiting
AGENT(S)

BL-8040

INFORMATION

Research Areas of Interest for Motixafortide

BioLineRx’s commitment to patients in need is supported not only through our own clinical studies, but also by supporting independent, unsolicited research relating to motixafortide by external investigators, organizations, and institutions as part of our Investigator Initiated Studies (IIS) program. IIS proposals submitted to BioLineRx are reviewed by our scientific and medical committees for scientific merit as well as safety, legal, ethical, and budgetary considerations. Support by BioLineRx can take the form of funding, study drug, or a combination of both.


Our research areas of interest include:

  • Stem cell mobilization
  • CXCR4 inhibition in immuno-oncology
  • Exploration of the role of motixafortide in reducing rates of myelosuppression
  • Pharmacoeconomic studies
  • Quality of life studies

To submit a proposal or for any further information please email IIS@biolinerx.com.

White Curve shaped
White Curve shaped
Drugs on the way to the finish line

Learn about our growing pipeline of best-in-class therapeutics for patients with cancer and rare disease.

DISCOVER OUR PIPELINE